Liver targeting and the delayed drug release of the nanoparticles of adriamycin polybutylcyanoacrylate in mice

Chinese Medical Journal

Volumn 119, Issue 15, 2006, Pages 1287-1293

  Shen, Liang Fang ^a   Zhang, Yang De ^a   Shen, Hai Ju ^a   Zeng, Shan ^a   Wang, Xin ^a   Wang, Cheng ^a   Le, Yuan ^a   Shen, Hong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Adriamycin; Liver targeting; Nanoparticles; Polybutylcyanoacrylate

Indexed keywords

CYANOACRYLATE DERIVATIVE; DOXORUBICIN; NANOPARTICLE; POLYBUTYLCYANOACRYLIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DELAYED DRUG RELEASE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG LIVER LEVEL; DRUG TARGETING; DRUG TISSUE LEVEL; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; LIVER; LIVER CANCER; LUNG; MOUSE; NONHUMAN; PARTICLE SIZE; SINGLE DRUG DOSE; SPLEEN; STATISTICAL SIGNIFICANCE; TAIL;

EID: 33747243409     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200608010-00009     Document Type: Article

References (24)

1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271-285.
2. Kreuter J. Nanoparticles and icroparticles for drug and vaccine delivery. J Anat 1996;189 (Pt 3):503-505.
3. Zhang ZR, He Q, Liao GT, Bai SH. Study on the anticarcinogenic effect and acute toxic of liver-targeting mitoxantrone nanoparticles. World J Gastroenterol 1999; 5:511-514.
4. Cho CS, Kobayashi A, Takei R. Recepter-mediated cell modulator delivery to hepatic using nanoparticles coated with carbohydrate-carryin polymers. Bioamaterials 2001; 22:45-51.
5. Zimmer A. Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers. Methods 1999;18:286-295.
6. Peracchia MT, Fattal E, Desmaele D, Besnard M, Noel JP, Gomis JM, et al. Stealth PEGYlated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release 1999;60:121-128.
7. Simeonova M, Ivanova T, Raikov Z, Konstantinov H. Tissue distribution of poly-butylcyanoacrylate nanoparticles loaded with spin-labelled nitrosourea lewis lung carcinoma bearing mice. Acta Physiol Pharmacol Bulg 1994;20:77-82.
8. Rolland A, Collet B, Le Verge R, Toccjas L. Blood clearance and organ distribution of intravenously administered polymethacrylic nanoparticles in mice. J Pharm Sci 1989;78:481-484.
9. Ensminger WD, Gyves JW. Early and delayed clinical cardiotoxity of doxorubilin. Cancer Treat Rep 1984; 68:101-105.
10. Mizuno I, Ichino T, Yotsuyanagi T, Akamo Y, Yamamoto T, Yasui T, et al. Clinical application of chemotherapy via the portal vein with liposome-encapsulated adriamycin in inoperable metastatic liver cancer. Gan To Kagaku Ryoho 1991;18:1878-1883.
11. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-314.
12. Mukherjee S, Banerjee SK, Maulik M, Dinda AK, Talwar KK, Maulik SK. Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression. BMC Pharmacol 2003;3:16.
13. Charman WN, Chan HK, Finnin BC, Charman SA. Drug delivery: A key factor in realising the full therapeutic potential of drugs. Drug Dev Res 1999;46:316-327.
14. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro and nanoparticles in drug delivery. J Controlled Release 2004;100:5-28.
15. 14C-labeled amino-modified polystyrene nanoparticles in mice. J Pharm Sci 1995;84:1249.
16. Allemann E, Leroux JC, Gurny R, Doelker E. In vitro extended-release properties of drug-loaded poly (DL-lactic acid) nanoparticles produced by a salting-out procedure. Pharm Res 1993;10:1732-1737.
17. Muller-Goymann CC. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm 2004; 58:343-356.
18. Huang ZQ. New methods for liver targeting therapy. In: Huang ZQ, eds. Liver operative surgery. People's Medical Publishing House: Beijing; 1996:38-39.
19. Lambert G, Fattal E, Couvreur P. Nanoparticulate systems for the delivery of antisense oligonucleotides. Adv Drug Deliv Rev 2001;47:99-112.
20. 3H-labelled dalargin bound to poly (butyl cyanoacrylate) nanoparticles after i.v. injections to mice. Life Sci 2000;66:495-502.
21. Zhang ZR, He Q. Study on liver targeting and hepatocytes permeable valaciclovir polybutylcyanoacrylate nanoparticles. World J Gastroenterol 1999; 5:330-333.
22. Zhang ZR, Lu W. Study on liver targeting and sustained release hydroxycamptothecin polybutylcyanoacrylate nanoparticles. Acta Pharm Sin 1997;32:222-227.
23. Banerjee T, Mitra S, Kumar Singh A, Kumar Sharma R, Maitra A. Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int J Pharm 2002;243:93-105.
24. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: Physicochemical characteristics and applications in MR imaging. Zur Radiol 2001;11:2319-2331.